Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
Foghorn Therapeutics and Eli Lilly will not advance FHD-909 (LY4050784) beyond the Phase 1 dose escalation trial after clinical data failed to show the required efficacy, and the collaboration — including the Selective SMARCA2 degrader program — will not move forward. Foghorn is now prioritizing its wholly owned pipeline: a Selective EP300 degrader, a novel oral immunology and inflammation program, a Selective CBP degrader, and its induced proximity platform. The company announced an approximately 40% workforce reduction and organizational changes expected to extend its cash runway into the second half of 2029.
Key figures
- Drug Name
- FHD-909 (LY4050784)
- Phase Of Trial
- Phase 1 dose escalation
- Cash runway
- into the second half of 2029
- Workforce reduction
- approximately 40%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.